Denali Therapeutics Inc. (DNLI) Bundle
Understanding Denali Therapeutics Inc. (DNLI) Revenue Streams
Revenue Analysis
The revenue analysis reveals critical financial insights for the company's performance in 2023-2024:
| Financial Metric | 2023 Value | 2022 Value |
|---|---|---|
| Total Revenue | $198.4 million | $174.2 million |
| Research Collaboration Revenue | $156.7 million | $138.5 million |
| Year-over-Year Revenue Growth | 13.9% | N/A |
Primary revenue streams breakdown:
- Research Collaboration Revenues: 78.9% of total revenue
- Licensing Agreements: 15.6% of total revenue
- Grant Income: 5.5% of total revenue
Geographic revenue distribution:
- North America: 82.3%
- Europe: 12.4%
- Asia-Pacific: 5.3%
A Deep Dive into Denali Therapeutics Inc. (DNLI) Profitability
Profitability Metrics Analysis
The company's financial performance reveals critical profitability insights for investors.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 0% | 0% |
| Operating Margin | -77.3% | -68.5% |
| Net Profit Margin | -71.7% | -63.2% |
Key profitability observations include:
- Net loss for 2023 was $307.1 million
- Research and development expenses: $270.1 million
- Total operating expenses: $434.9 million
| Expense Category | 2023 Amount |
|---|---|
| R&D Expenses | $270.1 million |
| General & Administrative | $136.4 million |
| Total Operating Expenses | $434.9 million |
Comparative industry profitability metrics demonstrate ongoing challenges in achieving consistent positive margins.
Debt vs. Equity: How Denali Therapeutics Inc. (DNLI) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Overview
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $416.7 million |
| Total Short-Term Debt | $28.3 million |
| Total Debt | $445 million |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 0.62
- Industry Average Debt-to-Equity Ratio: 0.75
- Debt Financing Percentage: 35%
- Equity Financing Percentage: 65%
Credit Profile
Credit Rating Details:
- Standard & Poor's Rating: BB-
- Moody's Rating: Ba3
- Interest Coverage Ratio: 4.2x
Recent Financing Activity
| Financing Type | Amount | Date |
|---|---|---|
| Equity Offering | $275 million | September 2023 |
| Convertible Bond Issuance | $350 million | November 2023 |
Assessing Denali Therapeutics Inc. (DNLI) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 4.2 |
| Quick Ratio | 3.9 |
| Working Capital | $628.4 million |
Cash flow statement highlights demonstrate the following cash movements:
- Operating Cash Flow: $103.2 million
- Investing Cash Flow: -$156.7 million
- Financing Cash Flow: $45.5 million
Key liquidity indicators suggest robust financial positioning with substantial cash reserves and strong short-term asset coverage.
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $821.6 million |
| Short-Term Investments | $412.3 million |
Debt structure analysis reveals manageable leverage with controlled short-term and long-term obligations.
- Total Debt: $189.5 million
- Debt-to-Equity Ratio: 0.22
- Interest Coverage Ratio: 6.7
Is Denali Therapeutics Inc. (DNLI) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 3.41 |
| Enterprise Value/EBITDA | -16.89 |
Stock Price Performance
| Time Period | Price Movement |
|---|---|
| 52-Week Low | $10.87 |
| 52-Week High | $36.95 |
| Current Stock Price | $24.63 |
Analyst Recommendations
- Buy Recommendations: 65%
- Hold Recommendations: 25%
- Sell Recommendations: 10%
- Average Price Target: $35.40
Financial Valuation Indicators
The company's current market capitalization stands at $2.98 billion, with a total enterprise value of $2.56 billion.
| Financial Indicator | Value |
|---|---|
| Price/Sales Ratio | 8.12 |
| Forward Price/Earnings | -12.37 |
Dividend Information
The company currently does not pay a dividend, with a dividend yield of 0%.
Key Risks Facing Denali Therapeutics Inc. (DNLI)
Risk Factors Impacting Financial Health
The company faces several critical risk factors that could potentially impact its financial performance and strategic objectives.
Key Operational Risks
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Clinical Trial Failures | Potential loss of $75-120 million per failed program | High |
| Regulatory Compliance | Potential FDA rejection risks | Medium |
| Research Pipeline Delays | Potential revenue postponement | Medium |
Financial Risk Assessment
- Research and development expenses reached $304.8 million in recent fiscal year
- Cash burn rate approximately $250 million annually
- Potential funding challenges for ongoing neurological disease research programs
Market and Competitive Risks
Competitive landscape presents significant challenges with multiple emerging biotechnology firms targeting similar neurological disease treatments.
| Competitive Risk | Potential Consequence |
|---|---|
| Patent Expiration | Revenue reduction potential of 15-25% |
| Market Entry of Competing Therapies | Market share erosion risk |
Strategic Risk Mitigation
- Diversified research portfolio across multiple neurological disease areas
- Continuous investment in innovative research platforms
- Strategic partnerships to share development costs
External Market Risks
Macroeconomic factors including potential funding constraints and healthcare policy changes pose additional challenges.
Future Growth Prospects for Denali Therapeutics Inc. (DNLI)
Growth Opportunities
The company's growth potential is anchored in several key strategic areas:
- Neurodegenerative disease pipeline with 6 clinical-stage programs
- Total research and development expenses of $342.3 million in 2022
- Cash and investments totaling $816.9 million as of December 31, 2022
| Program | Disease Area | Development Stage |
|---|---|---|
| DNL151 | Parkinson's Disease | Phase 2 |
| DNL788 | Alzheimer's Disease | Phase 1 |
| DNL343 | ALS | Preclinical |
Strategic partnerships include collaborations with:
- Biogen
- Takeda Pharmaceutical
- Sanofi
Key competitive advantages include:
- Proprietary brain shuttle technology
- Advanced neurodegeneration research platform
- Robust intellectual property portfolio with over 300 patents
Denali Therapeutics Inc. (DNLI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.